Market cap
$35.4m
End-of-day close multiplied by current shares on issue.
PHL · NZX
Promisia Healthcare (PHL)
Healthcare / Aged careCovered: FY22 - FY265 published briefings
Promisia Healthcare is an NZX-listed healthcare / aged care company with FY22 - FY26 of published result briefings.
Sections
Snapshot
Latest metrics
FY26, released 28 May 2026
← Swipe to view more
| Metric | Value | Change |
|---|---|---|
| Revenue | $40.1m | ↑ +34.0% |
| EBITDAF | $6.6m | — |
| NPAT | $12.9m | ↑ +706.3% |
| Operating cash flow | $6.4m | ↓ -15.1% |
| OCF / EBITDAF % | 96.2%Outside range low ocf / ebitda cash conversion. 96.2%; 3-period range 107.1% to 197.5%. OCF / EBITDA cash conversion: 96.2%, below normal range; 3-period mean 167.2%, range 107.1%-197.5%. | — |
| Net debt | $38.5m | ↑ +32.5% |
| Net debt / EBITDAF | 5.82x | — |
| ROE % | 23.4% | ↑ +16.1pp |
| DPS | 0.0c | — |
| PBT | $13.9m | ↑ +286.1% |
Source: latest published briefing (FY26, released 28 May 2026). Change compares against the prior equivalent period: FY24, released 29 May 2024.
Valuation
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
Prices as at close, 30 July 2026
Price and market cap
The latest close and share count context for the market price.
i
Profitability multiples
How the market price compares with recent earnings and cash-flow inputs.
P/E
2.74x
Recent market cap compared with trailing earnings.
EPS
0.24
Recent filing-derived earnings per share.
PEG
0.03x
P/E compared with recent earnings growth.
EV/EBITDA
11.17x
Enterprise value compared with recent EBITDA.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
0.64x
Market value compared with latest reported equity.
Income and fund shape
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Price history
Daily closes use the full available width, with hover and touch readouts against real observations. Expand opens the chart at reading size.
Share price
Five years of daily closes, as at close, 5 June 2026. Weekends, suspensions, and listing gaps stay as natural gaps in the time scale.
Loading chart...
P/E over time
Filing-period markers only: EOD close on or before each release date divided by filing-derived trailing NPAT where both inputs verify.
Loading chart...
Chat
Ask about PHL
Ask follow-up questions about Promisia Healthcare's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Ask about PHL
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
Performance over time
The latest period is shown first.
← Swipe to view more
| Metric | FY2612 MONTHS28 May 2026 | FY2412 MONTHS29 May 2024 | HY246 MONTHS28 November 2023 | FY2312 MONTHS30 May 2023 | FY2212 MONTHS30 June 2022 | Trend |
|---|---|---|---|---|---|---|
| Revenue | $40.1m | $29.9m | $12.9m | $23.8m | $19m | Chart |
| Revenue growth % | 29.1% | 25.6% | 10.7% | 25.5%Outside range low revenue growth. 25.5%; 3-period range 25.6% to 213.6%. Revenue growth: 25.5%, below normal range; 3-period mean 89.4%, range 25.6%-213.6%. | 213.6%Outside range high revenue growth. 213.6%; 3-period range 25.5% to 29.1%. Revenue growth: 213.6%, above normal range; 3-period mean 26.7%, range 25.5%-29.1%. | Chart
|
| EBITDAF | $6.6m | — | $1.6m | $3.6m | $4.5m | Chart |
| EBITDAF margin % | 16.5% | — | 12.4% | 15.0% | 23.5%Outside range high ebitda margin. 23.5%; 3-period range 12.7% to 16.5%. EBITDA margin: 23.5%, above normal range; 3-period mean 14.7%, range 12.7%-16.5%. | Chart
|
| PBT | $13.9m | $3.6m | -$0.1m | $0.5m | $1.9m | Chart |
| PBT growth % | 107.5% | 620.0% | — | -73.7% | — | Chart |
| NPAT | $12.9m | $1.6m | — | $0.7m | $2m | Chart |
| NPAT growth % | 89.7% | 128.6% | — | -65.0% | n/m | Chart |
| Operating cash flow | $6.4m | $7.5m | $2.1m | $7.1m | $4.8m | Chart |
| OCF / EBITDAF % | 96.2%Outside range low ocf / ebitda cash conversion. 96.2%; 3-period range 107.1% to 197.5%. OCF / EBITDA cash conversion: 96.2%, below normal range; 3-period mean 167.2%, range 107.1%-197.5%. | — | 129.6% | 197.5%Outside range high ocf / ebitda cash conversion. 197.5%; 3-period range 96.2% to 197.1%. OCF / EBITDA cash conversion: 197.5%, above normal range; 3-period mean 133.5%, range 96.2%-197.1%. | 107.1% | Chart
|
| FCF pre-lease | -$0.17m | — | — | -$6.8m | $4.3m | Chart |
| FCF post-lease | -$0.17m | — | — | — | $4.3m | Chart |
| DPS | 0.0c | — | — | — | — | — |
| ROE % | 23.4% | 7.3% | — | 3.4% | 10.9% | Chart |
| Net debt | $38.5m | $29m | $30.1m | $28.8m | $14.7m | Chart |
| Net debt / EBITDAF | 5.82x | — | 18.79x | 8.04xOutside range high net debt / ebitda. 8x; 3-period range 3.3x to 7.64x. Net debt / EBITDA: 8.00x, above normal range; 3-period mean 5.59x, range 3.30x-7.64x. | 3.3xOutside range low net debt / ebitda. 3.3x; 3-period range 5.82x to 8x. Net debt / EBITDA: 3.30x, below normal range; 3-period mean 7.15x, range 5.82x-8.00x. | Chart
|
| Debtor days | — | — | 32 | 22 | 20 | Chart |
| Total assets | $199.5m | $84.3m | $73.6m | $71.8m | $51.5m | Chart |
Reference: annolyse.ai/companies/phl
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
Filing-only history charts
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Revenue
Reported revenue across covered periods.
Loading chart...
Revenue growth
Like-period revenue growth where comparable.
Loading chart...
- FY22 PHL FY: Outside range high revenue growth. 213.6%; 3-period range 25.5% to 29.1%. Revenue growth: 213.6%, above normal range; 3-period mean 26.7%, range 25.5%-29.1%.
- FY23 PHL FY: Outside range low revenue growth. 25.5%; 3-period range 25.6% to 213.6%. Revenue growth: 25.5%, below normal range; 3-period mean 89.4%, range 25.6%-213.6%.
EBITDA-equivalent
Company-specific earnings measure where disclosed.
Loading chart...
EBITDA margin
EBITDA-equivalent margin where revenue and earnings are source-backed.
Loading chart...
- FY22 PHL FY: Outside range high ebitda margin. 23.5%; 3-period range 12.7% to 16.5%. EBITDA margin: 23.5%, above normal range; 3-period mean 14.7%, range 12.7%-16.5%.
NPAT
Statutory profit after tax.
Loading chart...
Operating cash flow
Cash generated from operations.
Loading chart...
Full chartable metric set
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
OCF / EBITDA
Cash conversion against earnings.
Loading chart...
- FY23 PHL FY: Outside range high ocf / ebitda cash conversion. 197.5%; 3-period range 96.2% to 197.1%. OCF / EBITDA cash conversion: 197.5%, above normal range; 3-period mean 133.5%, range 96.2%-197.1%.
- FY26 PHL FY: Outside range low ocf / ebitda cash conversion. 96.2%; 3-period range 107.1% to 197.5%. OCF / EBITDA cash conversion: 96.2%, below normal range; 3-period mean 167.2%, range 107.1%-197.5%.
FCF pre-lease
Operating cash flow less capex before leases.
Loading chart...
FCF post-lease
Free cash flow after lease payments where available.
Loading chart...
ROE
Return on equity.
Loading chart...
Net debt
Borrowings less cash; negative values indicate net cash.
Loading chart...
Net debt / EBITDA
Leverage ratio, suppressed where earnings are not meaningful.
Loading chart...
- FY22 PHL FY: Outside range low net debt / ebitda. 3.3x; 3-period range 5.82x to 8x. Net debt / EBITDA: 3.30x, below normal range; 3-period mean 7.15x, range 5.82x-8.00x.
- FY23 PHL FY: Outside range high net debt / ebitda. 8x; 3-period range 3.3x to 7.64x. Net debt / EBITDA: 8.00x, above normal range; 3-period mean 5.59x, range 3.30x-7.64x.
DPS
Dividend per share declared for the period.
Loading chart...
Debtor days
Receivables days where the working-capital inputs are source-backed.
Loading chart...
The setup & the reality
FY24 → FY26 Follow-through
The latest result is checked against what the prior briefing said to watch.
Historical setup
What FY24 said to watch
Previous analysisFY24Result releasedAnnolyse analysis published
From PBT surged on a 25.6% revenue lift driven by prior-year acquisition
No formal earnings targets were disclosed for FY24, so there is no stated benchmark against which to judge the result. Management's commentary emphasises second-half momentum, and the half-year shape supports this: first-half NPAT was a NZ$0.2m loss, meaning the NZ$1.8m implied second-half NPAT carried essentially all of the annual profit. The 10% operating revenue growth and declining underlying EBITDAF suggest the business is still embedding the acquisition and working through cost-base management, rather than demonstrating operational leverage.
The stated strategy centres on occupancy improvement, revenue diversification, and network growth — but no FY25 targets are given. Whether the second-half momentum can be sustained, and whether the underlying EBITDAF can return toward its prior-year level, are the key unresolved forward questions this release does not answer.
Open questions
Open questions from FY24
- What is the organic occupancy and revenue trajectory at the Aldwins House acquisition specifically, and is it contributing positively to EBITDAF yet?
- Why did underlying EBITDAF fall 8% despite a 10% increase in operating revenue, and what specific cost lines drove the margin compression?
- What deferred tax asset or liability movement produced the -54.6% effective tax rate, and when does the company expect to normalise toward a cash tax-paying position?
- How much undrawn facility capacity remains, and what are the banking covenant settings given net debt of approximately NZ$29.0m against a declining EBITDAF base?
- Will the company resume capital investment in FY25, and if so, at what scale relative to the NZ$13.9m FY23 spend?
This briefing cannot assess the recoverability of the deferred tax asset, the sustainability of second-half occupancy rates, or the terms of the debt facilities that underpin the company's financial flexibility.
Archive
Briefing archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
FY26 · Released 28 May 2026
FY26 NPAT $12.9m hinges on H2 swing; EBITDAF $6.6m the cleaner read
Full-year Cromwell consolidation and a sharp H2 earnings swing lift reported NPAT while net debt/EBITDAF falls to 5.8x.
Read briefing
FY24 · Released 29 May 2024
PBT surged on a 25.6% revenue lift driven by prior-year acquisition
Revenue growth of 25.6% flatters the comparison because FY23 included a major acquisition, while a negative effective tax rate of -54.6% inflates
Read briefing
HY24 · Released 28 November 2023
Revenue up 10.7% but PBT swung to a NZ$0.1m loss as costs outpaced growth
Promisia's aged-care operations grew the top line solidly, but earnings turned negative as cost growth absorbed the revenue gain, leaving a NPAT loss
Read briefing
FY23 · Released 30 May 2023
PBT fell 73.7% as revenue growth failed to offset cost expansion
A 25.5% revenue uplift was more than consumed by higher operating costs, lifting net debt to EBITDA to 8.0x and compressing PBT to NZ$0.5m.
Read briefing
FY22 · Released 30 June 2022
First full year of acquired aged-care lifts revenue to $19.0m
Headline +213.6% growth reflects the December 2020 acquisition lapping into a full period, not underlying expansion of the existing footprint.
Read briefing
Get notified when PHL publishes
Get the next Promisia Healthcare result briefing and five-year history updates by email.